Invesco Ltd. Has $403,000 Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Invesco Ltd. reduced its position in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 61.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 52,128 shares of the biotechnology company's stock after selling 84,036 shares during the quarter. Invesco Ltd. owned approximately 0.11% of REGENXBIO worth $403,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 2,510 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of REGENXBIO during the 4th quarter valued at about $54,000. Dynamic Technology Lab Private Ltd bought a new stake in REGENXBIO during the 4th quarter worth approximately $79,000. EntryPoint Capital LLC purchased a new position in REGENXBIO during the fourth quarter valued at approximately $97,000. Finally, Teacher Retirement System of Texas raised its position in shares of REGENXBIO by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company's stock valued at $97,000 after purchasing an additional 2,088 shares during the period. 88.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have commented on RGNX. Morgan Stanley boosted their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, March 14th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st. HC Wainwright cut their target price on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a report on Monday, March 17th. Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a research report on Tuesday, March 18th. Finally, Chardan Capital restated a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a report on Thursday, March 20th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $31.63.

REGENXBIO Trading Up 3.4 %

Shares of NASDAQ:RGNX traded up $0.24 during trading on Friday, hitting $7.39. 248,508 shares of the stock were exchanged, compared to its average volume of 843,937. The company has a market cap of $370.36 million, a PE ratio of -1.47 and a beta of 1.11. REGENXBIO Inc. has a 12-month low of $5.04 and a 12-month high of $16.85. The company has a fifty day moving average price of $7.29 and a two-hundred day moving average price of $8.03.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The business had revenue of $21.21 million for the quarter, compared to analysts' expectations of $23.70 million. Equities research analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.